Cargando…
How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmi...
Autores principales: | Jain, Arihant, Singh, Charanpreet, Dhawan, Rishi, Jindal, Nishant, Mohindra, Ritin, Lad, Deepesh, Prakash, Gaurav, Khadwal, Alka, Suri, Vikas, Bhalla, Ashish, Kumari, Savita, Varma, Neelam, John, M Joseph, Mahapatra, Manoranjan, Malhotra, Pankaj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274942/ https://www.ncbi.nlm.nih.gov/pubmed/32837051 http://dx.doi.org/10.1007/s12288-020-01300-0 |
Ejemplares similares
-
Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023) -
Chronic Lymphocytic Leukemia: Real-World Data From India
por: Tejaswi, V., et al.
Publicado: (2020) -
Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial)
por: Singh, Charanpreet, et al.
Publicado: (2022) -
Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience
por: Prakash, Gaurav, et al.
Publicado: (2021) -
Variation in Adherence Measures to Imatinib Therapy
por: Yanamandra, Uday, et al.
Publicado: (2017)